AGM
AUPH icon

Alpine Global Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Alpine Global Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,363
Closed -$84K – 167
2022
Q4 		$84K Buy
+19,363
New +$112K 0.03% 339

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alpine Global Management's AUPH Position: Q1 2023 in Review

Alpine Global Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2023, closing a stake of 19,363 shares — an estimated $84K sold.

Alpine Global Management first reported a position in AUPH in Q4 2022 and held it in 1 quarter. The position peaked at $84K in Q4 2022. 186 funds tracked by Wall St. Rank hold AUPH as of Q1 2023.

  • Alpine Global Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 19,363 Aurinia Pharmaceuticals shares in Q1 2023, an estimated $84K.
  • Alpine Global Management first reported a position in Aurinia Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Alpine Global Management's Aurinia Pharmaceuticals position peaked at $84K in Q4 2022.
  • 186 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.